Every Medication We Screen
Before Ibogaine Treatment

Washout is governed by half-life, active metabolites, and the specific risk mechanism. SSRIs and SNRIs (including sertraline and fluoxetine) are managed via onsite taper at MindScape under continuous physician supervision and telemetry, with twice-daily ibogaine TA booster doses bridging serotonergic tone. The HCl flood dose is administered only after titration to a protocol-defined safe threshold rather than after full pre-arrival washout. Fluoxetine still requires extended pre-arrival timing because its active metabolite norfluoxetine has a 4-16 day half-life. MAOIs require a strict 2-week pre-arrival washout because the interaction risk is non-titratable. Methadone requires pre-arrival transition to a short-acting opioid because of QT prolongation plus long opioid receptor occupancy. Every recommendation in this database is matched to the specific pharmacology of the drug.

CONTRAINDICATED means the medication cannot be combined with the ibogaine HCl flood dose at full strength. For most psychiatric medications (SSRIs, SNRIs, benzodiazepines, Z-drugs), this does not mean you are permanently ineligible and it does not mean you must complete the taper before arrival. Patients arrive on their current prescribed dose and the taper is performed onsite at MindScape with twice-daily ibogaine TA booster bridging under continuous physician supervision. The flood dose is administered only after titration to the protocol-defined safe threshold. Pre-arrival contraindications that DO require full clearance before travel are MAOIs, tricyclic antidepressants, lithium, tramadol, methadone, long-acting opioids, and Class III antiarrhythmics like amiodarone (40-55 day half-life), where in-clinic washout is impractical. In those cases the medical team works with your prescribing physician on the pre-arrival plan or on alternatives.

This database is curated against ibogaine specifically. Standard drug interaction tools flag serotonin reuptake inhibitors against each other but do not know about noribogaine's SERT activity, ibogaine's hERG affinity, or the practical washout windows used in psychedelic medicine clinics. Each entry is reviewed by physicians who supervise ibogaine sessions every week.

Contact our medical team for a manual review. Washout windows for less-common drugs depend on half-life, CYP involvement, QT effect, and serotonergic activity, all of which require clinician judgement. We screen 176 of the most common interacting medications and supplements; rare or compounded medications get individual workups.

Yes. Use our interactive Drug Interaction Checker. It searches the same database, supports brand names and aliases, and highlights every interaction in your medication list with severity, mechanism, and clinical action.

Dr. Arellano (Clinical Director, 1,000+ ibogaine sessions supervised) and Scott Gagel (Senior Medical Advisor, 25+ years U.S. clinical practice). The database is rebuilt against published QTc, CYP2D6, and serotonergic-drug references and re-reviewed at least every 90 days.